CME/CE

Episodes 97-111 of 111

• 

  MinuteCE®

  Improving the management of patients with atherosclerotic cardiovascular disease  - The evolving role of icosapent ethyl

  1.00 credit 3 episodes

  • 

    

    Erik Stroes

  • 

    

    P. Gabriel Steg, MD

  • 

    

    Pam R. Taub, MD, FACC, FASPC

  1.00 credit 3 episodes

• 

  RestartResume

  Perspectives on the results of recent clinical outcomes trials with EPA prevention 
  

  RestartResume

  Perspectives on the results of recent clinical outcomes trials with EPA prevention 
  

  MinuteCE®

  Perspectives on the results of recent clinical outcomes trials with EPA prevention 
  

  1.00 program credit

  • 

    

    P. Gabriel Steg, MD

  1.00 program credit

• 

  RestartResume

  The evolving need and challenges to reach LDL-c targets in high-risk patients 
  

  RestartResume

  The evolving need and challenges to reach LDL-c targets in high-risk patients 
  

  MinuteCE®

  The evolving need and challenges to reach LDL-c targets in high-risk patients 
  

  1.00 program credit

  • 

    

    Kausik Ray, MBChB, MD, MPhil

  1.00 program credit

• 

  RestartResume

  PCSK9i: Benefits across the spectrum of cardiovascular disease 
  

  RestartResume

  PCSK9i: Benefits across the spectrum of cardiovascular disease 
  

  MinuteCE®

  PCSK9i: Benefits across the spectrum of cardiovascular disease 
  

  1.00 program credit

  • 

    

    Prof. dr. Fabrice Martens

  1.00 program credit

• 

  MinuteCE®

  The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management

  1.00 credit 4 episodes

  • 

    

    Kausik Ray, MBChB, MD, MPhil

  • 

    

    Lale Tokgözoğlu, MD

  • 

    

    Prof. dr. Fabrice Martens

  • 

    

    Erin Michos

  1.00 credit 4 episodes

• 

  RestartResume

  Oral cholesterol-lowering therapies: The basis of prevention 
  

  RestartResume

  Oral cholesterol-lowering therapies: The basis of prevention 
  

  MinuteCE®

  Oral cholesterol-lowering therapies: The basis of prevention 
  

  1.00 program credit

  • 

    

    Lale Tokgözoğlu, MD

  1.00 program credit

• 

  RestartResume

  Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi 
  

  RestartResume

  Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi 
  

  MinuteCE®

  Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi 
  

  1.00 program credit

  • 

    

    Erin Michos

  1.00 program credit

• 

  RestartResume

  Unmet needs in lowering LDL-c

  RestartResume

  Unmet needs in lowering LDL-c

  MinuteCE®

  Unmet needs in lowering LDL-c

  1.00 program credit

  • 

    

    Stephen Nicholls, FRACP, FACC, FESC, FAHA

  1.00 program credit

• 

  MinuteCE®

  Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?

  1.00 credit 3 episodes

  • 

    

    Stephen Nicholls, FRACP, FACC, FESC, FAHA

  • 

    

    Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  • 

    

    Roxana Mehran, MD

  1.00 credit 3 episodes

• 

  RestartResume

  New insights on CETP inhibition from genetic research and clinical trials

  RestartResume

  New insights on CETP inhibition from genetic research and clinical trials

  MinuteCE®

  New insights on CETP inhibition from genetic research and clinical trials

  1.00 program credit

  • 

    

    Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  1.00 program credit

• 

  RestartResume

  Exploring the role of a novel CETP inhibitor in lipid management

  RestartResume

  Exploring the role of a novel CETP inhibitor in lipid management

  MinuteCE®

  Exploring the role of a novel CETP inhibitor in lipid management

  1.00 program credit

  • 

    

    Roxana Mehran, MD

  1.00 program credit

• 

  MinuteCE®

  Seeing the forest through the trees  - Diagnosing and treating hypertrophic cardiomyopathy

  1.00 credit 3 episodes

  • 

    

    Antonis Pantazis, MD

  • 

    

    Pablo García-Pavía, MD, PhD

  • 

    

    Carolyn Ho, MD

  1.00 credit 3 episodes

• 

  RestartResume

  Hypertrophic cardiomyopathy: What are the concerns?

  RestartResume

  Hypertrophic cardiomyopathy: What are the concerns?

  MinuteCE®

  Hypertrophic cardiomyopathy: What are the concerns?

  1.00 program credit

  • 

    

    Antonis Pantazis, MD

  1.00 program credit

• 

  RestartResume

  Improving quality of life in patients with HCM

  RestartResume

  Improving quality of life in patients with HCM

  MinuteCE®

  Improving quality of life in patients with HCM

  1.00 program credit

  • 

    

    Carolyn Ho, MD

  1.00 program credit

• 

  RestartResume

  Diagnostic challenges for symptomatic obstructive HCM

  RestartResume

  Diagnostic challenges for symptomatic obstructive HCM

  MinuteCE®

  Diagnostic challenges for symptomatic obstructive HCM

  1.00 program credit

  • 

    

    Pablo García-Pavía, MD, PhD

  1.00 program credit